All In Biotech

Drug Trial Radar · NCT06551324

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 609 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

609

Actual

Start

Oct 21, 2024

Primary completion

Feb 28, 2027

Study completion Oct 29, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

  • PF-06821497Drug

    875 mg BID (2 times a day)

  • DocetaxelDrug

    75 mg/m2 IV (every 21 days)

  • EnzalutamideDrug

    160 mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Time frame: Randomization up to approximately 2 years.

Locations

224 sites in 23 countries. Site status is shown where the registry gives one.

  • Urology Centers of Alabama

    Homewood, Alabama

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Ironwood Cancer & Research Centers

    Gilbert, Arizona

  • Ironwood Cancer & Research Centers

    Glendale, Arizona

  • Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Cancer & Research Centers

    Phoenix, Arizona

  • Ironwood Cancer & Research Centers

    Scottsdale, Arizona

  • Los Angeles Cancer Network

    Anaheim, California

  • UCSF Cancer Center Berkeley

    Berkeley, California

  • UCSF Cancer Center Burlingame

    Burlingame, California

  • Los Angeles Cancer Network

    Fountain Valley, California

  • Los Angeles Cancer Network

    Glendale, California

  • Los Angeles Cancer Network

    Glendale, California

  • Los Angeles Cancer Network

    Los Angeles, California

  • Los Angeles Cancer Network

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • UCSF Investigational Drug Pharmacy

    San Francisco, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • UCSF Cancer Center San Mateo

    San Mateo, California

  • Sutter Santa Rosa

    Santa Rosa, California

  • Stanford Health Care Attention: Investigational Pharmacy

    Stanford, California

  • Colorado Clinical Research

    Lakewood, Colorado

  • University of Miami Sylvester Comprehensive Cancer Center - Aventura

    Aventura, Florida

  • Florida Cancer Specialists

    Bradenton, Florida

  • Florida Cancer Specialists

    Cape Coral, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    Coral Gables, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Deerfield Beach

    Deerfield Beach, Florida

  • University of Miami Hospital and Clinics - Doral

    Doral, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    Fort Myers, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Kendall

    Kendall, Florida

  • University of Miami Hospital and Clinics, Sylvester Cancer Center

    Miami, Florida

  • University of Miami Hospital and Clinics, UHealth Tower

    Miami, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Griffin Cancer Research Building

    Miami, Florida

  • Florida Cancer Specialists

    N. Venice, Florida

  • Florida Cancer Specialists

    Naples, Florida

  • AdventHealth Hematology and Oncology

    Orlando, Florida

  • AdventHealth Orlando Infusion Center

    Orlando, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Plantation

    Plantation, Florida

Showing 40 of 224 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.